Solara Active Pharma Sciences Ltd
NSE:SOLARA
Balance Sheet
Balance Sheet Decomposition
Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd
Balance Sheet
Solara Active Pharma Sciences Ltd
| Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
471
|
757
|
560
|
1 977
|
464
|
87
|
86
|
41
|
|
| Cash |
11
|
36
|
12
|
32
|
39
|
87
|
2
|
2
|
|
| Cash Equivalents |
460
|
721
|
548
|
1 945
|
425
|
1
|
84
|
40
|
|
| Short-Term Investments |
144
|
0
|
0
|
0
|
425
|
1
|
54
|
8
|
|
| Total Receivables |
2 647
|
3 341
|
3 114
|
5 428
|
6 037
|
6 074
|
3 970
|
3 810
|
|
| Accounts Receivables |
2 625
|
2 888
|
2 265
|
4 839
|
4 927
|
5 382
|
3 485
|
3 266
|
|
| Other Receivables |
22
|
453
|
849
|
589
|
1 110
|
691
|
485
|
544
|
|
| Inventory |
1 877
|
2 308
|
2 960
|
3 005
|
5 800
|
5 613
|
3 710
|
3 274
|
|
| Other Current Assets |
944
|
74
|
85
|
167
|
93
|
102
|
243
|
164
|
|
| Total Current Assets |
6 082
|
6 481
|
6 720
|
10 576
|
12 393
|
11 875
|
8 008
|
7 287
|
|
| PP&E Net |
6 756
|
7 610
|
9 516
|
9 992
|
11 374
|
11 591
|
11 142
|
10 765
|
|
| PP&E Gross |
0
|
7 610
|
9 516
|
9 992
|
11 374
|
11 591
|
11 142
|
10 765
|
|
| Accumulated Depreciation |
0
|
928
|
1 754
|
2 671
|
3 622
|
4 455
|
5 155
|
5 967
|
|
| Intangible Assets |
1 008
|
1 029
|
923
|
800
|
679
|
544
|
426
|
298
|
|
| Goodwill |
3 634
|
3 651
|
3 651
|
3 651
|
3 651
|
3 651
|
3 651
|
3 649
|
|
| Note Receivable |
27
|
311
|
354
|
409
|
339
|
59
|
84
|
112
|
|
| Long-Term Investments |
312
|
297
|
288
|
257
|
250
|
256
|
41
|
40
|
|
| Other Long-Term Assets |
445
|
223
|
84
|
451
|
763
|
1 017
|
158
|
168
|
|
| Other Assets |
3 634
|
3 651
|
3 651
|
3 651
|
3 651
|
3 651
|
3 651
|
3 649
|
|
| Total Assets |
18 263
N/A
|
19 601
+7%
|
21 535
+10%
|
26 136
+21%
|
29 450
+13%
|
28 993
-2%
|
23 510
-19%
|
22 318
-5%
|
|
| Liabilities | |||||||||
| Accounts Payable |
3 129
|
2 444
|
2 161
|
3 093
|
2 760
|
3 059
|
3 130
|
2 486
|
|
| Accrued Liabilities |
13
|
21
|
26
|
23
|
44
|
43
|
54
|
132
|
|
| Short-Term Debt |
3 302
|
2 145
|
3 538
|
3 609
|
6 099
|
6 488
|
7 603
|
5 729
|
|
| Current Portion of Long-Term Debt |
598
|
986
|
1 227
|
933
|
1 337
|
1 178
|
1 338
|
916
|
|
| Other Current Liabilities |
341
|
960
|
347
|
230
|
394
|
244
|
304
|
178
|
|
| Total Current Liabilities |
7 382
|
6 555
|
7 299
|
7 888
|
10 634
|
11 011
|
12 429
|
9 441
|
|
| Long-Term Debt |
2 429
|
2 250
|
2 455
|
1 666
|
2 937
|
2 463
|
1 174
|
1 316
|
|
| Deferred Income Tax |
532
|
328
|
118
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
45
|
44
|
43
|
42
|
23
|
22
|
27
|
27
|
|
| Other Liabilities |
236
|
865
|
761
|
655
|
606
|
495
|
541
|
592
|
|
| Total Liabilities |
10 623
N/A
|
10 042
-5%
|
10 676
+6%
|
10 251
-4%
|
14 201
+39%
|
13 991
-1%
|
14 171
+1%
|
11 376
-20%
|
|
| Equity | |||||||||
| Common Stock |
247
|
258
|
269
|
359
|
360
|
360
|
360
|
403
|
|
| Retained Earnings |
0
|
470
|
1 444
|
3 427
|
2 747
|
2 504
|
3 159
|
3 123
|
|
| Additional Paid In Capital |
0
|
8 846
|
9 166
|
12 117
|
12 160
|
12 160
|
12 160
|
13 687
|
|
| Other Equity |
7 393
|
15
|
19
|
18
|
19
|
22
|
23
|
23
|
|
| Total Equity |
7 640
N/A
|
9 559
+25%
|
10 859
+14%
|
15 885
+46%
|
15 249
-4%
|
15 002
-2%
|
9 339
-38%
|
10 942
+17%
|
|
| Total Liabilities & Equity |
18 263
N/A
|
19 601
+7%
|
21 535
+10%
|
26 136
+21%
|
29 450
+13%
|
28 993
-2%
|
23 510
-19%
|
22 318
-5%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
25
|
26
|
27
|
39
|
39
|
39
|
39
|
48
|
|